Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is enzymatically converted to SN‑38, a potent inhibitor of topoisomerase I. By blocking the re‑ligation step of DNA replication, SN‑38 causes accumulation of DNA breaks, leading to apoptosis of rapidly dividing cancer cells. Metabolism and clearance are influenced by liver enzymes, especially UGT1A1.

The dose of Irinotecan Accord is individualized by the prescribing oncologist based on factors such as the patient’s body surface area, disease stage, prior therapies, liver function, and genetic markers like UGT1A1 genotype. No fixed dosing schedule is provided here; the prescriber sets the regimen.

Safety data for Irinotecan during pregnancy and lactation are limited. It is classified as pregnancy category unknown, and the drug can cross the placenta and be excreted in breast milk. Use is only considered when the potential benefit outweighs the potential risk to the fetus or infant.

To order Irinotecan Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, with topotecan being a closely related alternative. Compared with topotecan, irinotecan is typically used for colorectal cancer and has a distinct metabolic pathway producing SN‑38. Oxaliplatin, a platinum‑based agent, is another common partner in colorectal regimens but works via DNA cross‑linking rather than topoisomerase inhibition.

Irinotecan Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Once reconstituted, follow the manufacturer’s stability guidelines for use within the recommended time frame.

Irinotecan Accord is given as an intravenous infusion, usually over 30 to 90 minutes depending on the protocol. The infusion is performed in a clinical setting by qualified healthcare professionals, with pre‑medication and monitoring for infusion‑related reactions as per institutional guidelines.

The most serious risks include severe neutropenia or febrile neutropenia, which can lead to life‑threatening infections; severe or delayed diarrhea that may progress to colitis; hypersensitivity reactions ranging from rash to anaphylaxis; and hepatic toxicity. Patients should be monitored closely for these events throughout treatment.

Irinotecan Accord should be avoided in patients with known hypersensitivity to irinotecan or any component of the formulation, those with severe hepatic impairment, and individuals with uncontrolled infections. Caution is also advised for patients with significant bone‑marrow suppression or those taking interacting medications that could increase toxicity.